bioRxiv ScienceSearch

Biology subjects

Shimizu, T.

Publications and source records attributed to Shimizu, T..

2 recordsLinked to original sources

Role of the high-affinity leukotriene B4 receptor signaling in fibrosis after unilateral ureteral obstruction in mice

Leukotriene B4 (LTB4) is a lipid mediator that acts as a potent chemoattractant for inflammatory leukocytes. Kidney fibrosis is caused by migrating inflammatory cells and kidney-resident cells. Here, we examined the role of the high-affinity LTB4 receptor BLT1 during development of kidney fibrosis in wild-type (WT) mice and BLT1 knockout (BLT1-/-) mice with unilateral ureteral obstruction (UUO). We found elevated expression of 5-lipoxygenase (5-LOX), which generates LTB4, in the renal tubules of WT and BLT1-/- UUO mice. Accumulation of immunoreactive type I collagen in UUO kidneys of WT mice increased over time; however, the increase was less prominent in BLT1-/- mice. Accumulation of S100A4-positive fibroblasts also increased temporally in WT UUO kidneys, but was again less pronounced in those of BLT1-/- mice. The same was true of mRNA encoding transforming growth factor-{beta} (TGF)-{beta} and fibroblast growth factor (FGF)-2. Finally, accumulation of F4/80-positive macrophages, which secrete TGF-{beta}, also increased temporally in WT UUO and BLT1-/- kidneys, but to a lesser extent in the latter. Following LTB4 stimulation in vitro, macrophages showed increased expression of mRNA encoding TGF-{beta}/FGF-2 and Col1a1, whereas L929 fibroblasts showed increased expression of mRNA encoding smooth muscle actin (SMA). Bone marrow (BM) transplantation studies revealed that the area positive for type I collagen was significantly smaller in BLT1-/--BM[->]WT UUO kidneys than in WT-BM[->]WT kidneys. Thus, LTB4-BLT1 signaling plays a critical role in fibrosis in UUO kidneys by increasing accumulation of macrophages and fibroblasts. Therefore, blocking BLT1 may prevent renal fibrosis.

pharmacology and toxicology

Assessment of urinary pharmacodynamic profiles of faropenem against extended-spectrum β-lactamase-producing Escherichia coli with canine ex vivo modeling

Extended-spectrum {beta}-lactamase (ESBL)-producing bacteria are of great concern in companion animals with urinary tract infections (UTIs). Because of its high safety and stability in the presence of ESBLs, faropenem is assumed to be a candidate antimicrobial agent for canine UTIs with ESBL-producing bacteria. This study was performed to investigate the urinary pharmacokinetics and pharmacodynamics of faropenem administered at 5 mg/kg body weight in six healthy dogs using an ex vivo model. Six UTI pathogenic strains of ESBL-producing Escherichia coli (ESBL-EC) with the following faropenem minimum inhibitory concentrations (MICs) were used: 1 {micro}g/mL (n = 2), 2 {micro}g/mL (n = 2), 4 {micro}g/mL (n = 1), and 16 {micro}g/mL (n = 1). Urine samples were obtained every 4 h for the first 12 h after faropenem administration for measurement of the urine drug concentration and urinary bactericidal titers (UBTs). The urine concentration of faropenem peaked at 0 to 4 h after administration, with a mean maximum concentration of 584 g/mL, and markedly decreased at 8 to 12 h (23 g/mL). The median UBTs for all tested ESBL-EC strains were highest at 0 to 4 h and then significantly decreased at 8 to 12 h. These findings indicate that administration of faropenem more than once daily is recommended for the treatment of ESBL-EC-related UTIs in dogs. In addition, the median areas under the UBT-time curves (AUBTs) were significantly inversely correlated with the corresponding MICs for faropenem in the tested strains (P < 0.05). Notably, the median AUBTs were significantly higher in ESBL-EC strains with an MIC of 1 {micro}g/mL than in those with an MIC of [&ge;]4 {micro}g/mL (P < 0.05). The present study serves as the basis of clinical application of faropenem for ESBL-producing bacteria-related UTIs in dogs.

microbiology